Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 305 results
Filters: First Letter Of Title is L  [Clear All Filters]
Found 305 results.

Adult

Dubé MP, Komarow L, Mulligan K, et al. "Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384." J. Acquir. Immune Defic. Syndr.. 2007;45(5):508-14.
Livingston EG, Cohn SE, Yang Y, et al. "Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy." Obstet Gynecol. 2007;110(2 Pt 1):391-7.
Taiwo BO, Chan ES, Fichtenbaum CJ, et al. "Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study." Clin. Infect. Dis.. 2015;61(7):1179-88.
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. "Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)." HIV Clin Trials. 2009;10(6):343-55.
Lok JJ, Bosch RJ, Benson CA, et al. "Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection." AIDS. 2010;24(12):1867-76.
Boswell KL, Paris R, Boritz E, et al. "Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection." PLoS Pathog.. 2014;10(1):e1003853.
Wohl DA, Kendall MA, Andersen J, et al. "Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030." HIV Clin Trials. 2009;10(3):143-52.
Kumarasamy N, Aga E, Ribaudo HJ, et al. "Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230." Clin. Infect. Dis.. 2015;60(10):1552-8.
Grant PM, Kitch D, McComsey GA, et al. "Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation." Clin. Infect. Dis.. 2013;57(10):1483-8.
Smith DM, Strain MC, Frost SDW, et al. "Lack of neutralizing antibody response to HIV-1 predisposes to superinfection." Virology. 2006;355(1):1-5.
Bartlett JA, Ribaudo HJ, Wallis CL, et al. "Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings." AIDS. 2012;26(11):1345-54.
Gandhi RT, McMahon DK, Bosch RJ, et al. "Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation." PLoS Pathog.. 2017;13(4):e1006285.
Swindells S, Jiang H, A Mukherjee L, Winters M, Bosch RJ, Katzenstein D. "Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(2):79-88.
Tsibris AMN, Paredes R, Chadburn A, et al. "Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211." Clin. Infect. Dis.. 2009;48(5):642-9.

Animals

Lederman MM, Margolis L. "The lymph node in HIV pathogenesis." Semin. Immunol.. 2008;20(3):187-95.

Pages